Development
Acrivon Therapeutics, Inc.
ACRV
$1.35
$0.108.00%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 235.28% | 229.12% | 279.62% | 252.98% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 107.53% | 146.20% | 112.19% | 101.79% | -- |
| Operating Income | -107.53% | -146.20% | -112.19% | -101.79% | -- |
| Income Before Tax | -88.35% | -125.98% | -95.93% | -91.88% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -88.35% | -125.98% | -95.93% | -91.88% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.35% | -125.98% | -95.93% | -91.88% | -- |
| EBIT | -107.53% | -146.20% | -112.19% | -101.79% | -- |
| EBITDA | -107.57% | -145.51% | -110.66% | -99.99% | -- |
| EPS Basic | 82.16% | 35.79% | 7.66% | -42.93% | -- |
| Normalized Basic EPS | 81.39% | 34.77% | 6.59% | -43.60% | -- |
| EPS Diluted | 82.16% | 35.79% | 7.66% | -42.93% | -- |
| Normalized Diluted EPS | 81.39% | 34.77% | 6.59% | -43.60% | -- |
| Average Basic Shares Outstanding | 987.39% | 701.96% | 420.30% | 135.25% | -- |
| Average Diluted Shares Outstanding | 987.39% | 701.96% | 420.30% | 135.25% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |